


WHAT IS CLAIMED IS:

1. A compound structurally represented by Formula I,



- 5 or pharmaceutically acceptable salts thereof, wherein:

R¹ and R² are independently H, or -O R³ N R⁴ R⁵, provided only one of R¹ and R² can be -O R³ N R⁴ R⁵;

R³ is (C₂-C₅) alkylene;

R⁴ is (C₁-C₄) alkyl;

- 10 R⁵ is (C₁-C₄) alkyl,

wherein R⁴ and R⁵ taken together with the nitrogen atom to which they are attached can form a piperidinyl or pyrrolidinyl ring;

X is CH₂ or CO;

Y and Z are -CH₂- or N, provided only one of Y and Z can be N;

- 15 R⁶ is hydrogen,

- (C₁-C₄) alkyl,

-CH₂ -phenyl,

-CH₂ (C₃-C₇) cycloalkyl,

-CO₂R⁸,

- 20 -SO₂R⁹,

-CONH R¹⁰,

-COR¹¹,

-CH₂CH₂N R¹² R¹³, or

-CH₂R¹⁴;

R⁷ is hydrogen,

- (C₁-C₄) alkyl,

-CH₂ - phenyl,

-CH₂(C₃-C₇) cycloalkyl,

5 -CO₂R⁸,

-SO₂R⁹,

-CONH R¹⁰,

-COR¹¹,

-CH₂CH₂N R¹² R¹³, or

10 -CH₂R¹⁴;

Wherein;

R⁸ is

- (C₁-C₄) alkyl, or

- (C₃-C₇) cycloalkyl;

15 R⁹ is

- (C₁-C₄) alkyl,

- (C₃-C₇) cycloalkyl, or

- phenyl;

R¹⁰ is

20 - (C₁-C₄) alkyl, or

- (C₃-C₇) cycloalkyl;

R¹¹ is

- (C₁-C₄) alkyl,

- (C₃-C₇) cycloalkyl,

25 -CH₂N R¹² R¹³, or

- (C₃-C₇) cycloalkyl, wherein optionally one or more of said carbons is replaced
by N, NR¹⁰, or NCO₂ R¹⁰;

R¹² is

- hydrogen, or
- (C₁-C₄) alkyl;






R¹³ is







- 5
- hydrogen,
 - (C₁-C₄) alkyl,
 - CO₂R¹⁰, or
 - phenyl;








R¹⁴ is








- 10
- (C₁-C₄) alkyl, or
 - (C₃-C₇) cycloalkyl, wherein optionally one or more of said carbons is replaced by N, NR¹⁰, or NCO₂R¹⁰.









2. The compound of claim 1, wherein R² is hydrogen and R¹ is -O R³ N R⁴ R⁵.
3. The compound of claim 2 wherein R³ is -CH₂CH₂CH₂-.
- 15 4. The compound of any of claims 1-3 wherein R⁴ and R⁵ taken together with the nitrogen atom to which they are attached form a piperidiny ring.
5. The compound of any of claims 1-4 wherein Z is N and Y is CH₂.
6. The compound of any of claims 1-4 wherein Y is N and Z is CH₂.
7. The compound of any of claims 1-6 wherein X is CO.
- 20 8. The compound of claim 1 further selected from the group consisting of:




	Example Number	Structure		
	1	 <chem>CC(C)(C)OC(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21</chem>		
	2	 <chem>C1CCc2ccc(OCCCN3CCCCC3)cc21</chem>		
	3	 <chem>CC1C(=O)N(C1)C(=O)N2CCc3ccc(OCCCN4CCCCC4)cc32</chem>		
	4	 <chem>c1ccccc1CN2CCc3ccc(OCCCN4CCCCC4)cc32</chem>		
	5	 <chem>C1CCCCC1CN2CCc3ccc(OCCCN4CCCCC4)cc32</chem>		

	6			
	7			
	8			
	9			
	10			
	11			

	12			
	13			
	14			
	15			
	16			
	17			
	18			

	19			
	20			
	21			
	22			
	23			
	24			
	25			

	26			
	27			
	28			
	29			
	30			
	31			
	32	 Chiral		
	33	 Chiral CH CH		

	34			
	35			
	36			

or a pharmaceutically acceptable salt or solvate thereof.

9. A pharmaceutical composition which comprises a compound of any of claims 1-8 and a pharmaceutically acceptable carrier.

10. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists comprising a compound of any of claims 1-8.

11. The method of Claim 10 wherein the antagonist is a pharmaceutical composition of claim 9.

12. The method of Claim 10 wherein the antagonist is characterized by having little or no binding affinity for the histamine receptor H4R.

13. A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-8.

14. The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 9.

15. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any

of claims 1-8.